<DOC>
	<DOCNO>NCT00834327</DOCNO>
	<brief_summary>This clinical trial conduct multiple site USA . Patients diagnose moderate severe Restless Legs Syndrome randomly allocate one 5 treatment arm study . The 5 arm include 4 arm different dos aplindore MR tablets 1 placebo arm . The treatment take day . The study blind neither patient , investigator , know treatment patient receiving . Patients assign dose maintain dose several week ( 2 treatment arm include short titration period ) . The entire study take 6 week . The study measure effective aplindore decreasing symptom Restless Legs Syndrome , also assess safety tolerability aplindore .</brief_summary>
	<brief_title>Efficacy Safety Study Aplindore Patients With Restless Legs Syndrome</brief_title>
	<detailed_description>Two hundred thirty patient randomly assign one five treatment arm outpatient study . Of four aplindore arm , two arm titrate brief period target dose achieve , arm , maintain several week . Dosing take place total 4 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Male female 1885 year ; Must score ≥20 IRLS Day 1 ( Baseline ) Visit ; Have history moderate severe RLS symptom disrupt sleep least 3 night per week least 3 month period either immediately screen prior start RLS treatment ; Patients must dopamine agonist medication take RLS minimum one week 5 half life RLS medication whichever longer , prior Day 1 ( Baseline ) Visit ; Patients must good general health determine thorough medical history physical examination ( include vital sign ) , 12lead electrocardiogram ( ECG ) ; Patients must clinical laboratory value within normal reference range must clinically significantly abnormal judge Investigator screening ; Females childbearing potential must use acceptable method contraception , negative serum pregnancy test screening , negative urine pregnancy test baseline . Acceptable method contraception include oral , intrauterine , implantable , injectable contraceptive , hormonal patch , double barrier method condom impregnate spermicide . After screen , patient use oral contraceptive method contraception must agree add additional method 30 day follow last dose study medication . Women oral contraceptive must use least one month prior screen ; Male patient partner childbearing potential must agree use adequate contraception ( use condom spermicidal ) study 3 month study ; Female patient surgically sterilize eligible negative pregnancy test screen Baseline ; If receive hormone replacement therapy , patient must stable regimen minimum 3 month prior screen ; Patients must able read , understand , provide written/dated informed consent enrol study , must willing comply study procedure . Clinically significant unstable medical illness ; Clinically significant allergic , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease ; History nonbasal cell cancer squamous cell cancer carcinoma situ cervix within 2 year screen visit exclude ; cancer diagnosis , patient history within 5 year screen visit exclude ; Patients plasma ferritin level less 10 ng/mL screening ; A supine blood pressure &gt; 140/90 mm/Hg screen baseline ; Patients take OTC prescription medication , judgment investigator , exacerbate cause RLS symptom exclude study ; Patients take prescription drug therapy counter ( OTC ) medication chronic medical condition RLS stable dos least two month prior screen ; patient investigational drug least 30 day prior screen ; History chronic use dopamine antagonists 6 month within past 2 year ; History presence chronic pain associate RLS . Patients exclude preponderance patient 's complaint related pain associate urge move ; Clinically significant narcolepsy , parasomnia adult , significant circadian rhythm disorder , secondary cause RLS , ( e.g. , uremia neuropathy ) ; Any condition may affect oral drug absorption ; Travel across three time zone , expect change sleep schedule 6 hour , involvement night shift work within seven day prior screen study completion ; Any clinically significant abnormal find Screening Visit physical examination , vital sign , ECG , determine Investigator ; ( The QTcF interval must ≤ 450 msec male ≤ 470 msec female ) ; History allergy , know sensitivity , hypersensitivity , adverse reaction aplindore structurally similar compound flesinomax , ropinirole ziprasadone ; Pregnant lactating female ; Recent history ( ≤ one year ) alcohol drug abuse , current evidence substance dependence abuse define DSMIV criterion ; Regular consumption large amount xanthinecontaining substance ( i.e . 10 cup coffee equivalent amount xanthinecontaining substance per day ) ; Prior exposure aplindore ; Patients deem high risk category sleep apnea determine Modified Berlin Questionnaire ; Patients fail prior treatment dopamine agonist evidence lack efficacy maximum tolerate dose ; Patients test positive Screening hepatitis B surface antigen hepatitis C antiboby history positive result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>